24 Aug
2021

AbbVie looks set to recreate Humira patent thicketing success following Imbruvica victory

US federal district court in Delaware finds four patents for blockbuster drug, Imbruvica valid and infringed in a boost that suggests AbbVie will not face competition until 2032.

Adam Houldsworth

Author | Life sciences reporter

[email protected]

Adam Houldsworth